This Article Full Text Full Text (PDF) All Versions of this Article: 50/1/130    most recent HYPERTENSIONAHA.106.084103v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cavasin, M. A. Articles by Carretero, O. A. Search for Related Content PubMed PubMed Citation Articles by Cavasin, M. A. Articles by Carretero, O. A. Related Collections Cardio-renal physiology/pathophysiology Structure Other myocardial biology Remodeling Other Vascular biology

(Hypertension. 2007;50:130.)
© 2007 American Heart Association, Inc.

Original Articles

Decreased Endogenous Levels of Ac-SDKP Promote Organ Fibrosis

Maria A. Cavasin; Tang-Dong Liao; Xiao-Ping Yang; James J. Yang; Oscar A. Carretero

From the Hypertension and Vascular Research Division (M.A.C., T.-D.L., X.-P.Y., O.A.C.), and Biostatistics and Research Epidemiology (J.J.Y.), Henry Ford Sciences Center, Henry Ford Health System, Detroit, Mich.

Correspondence to Oscar A. Carretero, Hypertension and Vascular Research Division, Henry Ford Health System, 2799 West Grand Blvd, E&R 7115, Detroit, MI 48202. E-mail ocarret1{at}hfhs.org or Maria A. Cavasin, In Vivo Pharmacology, Gilead Colorado, 7577 W 103rd Ave, Ste 212, Westminster, CO 80021. E-mail maria.cavasin@gilead.com

There is convincing evidence that chronic treatment with N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), a peptide normally found in tissues and biological fluids, reduces collagen deposition in the heart and kidneys of hypertensive rats and rats with myocardial infarction. However, it is not known whether endogenous Ac-SDKP at basal concentrations has any physiological function related to collagen deposition. Prolyl oligopeptidase is responsible for release of Ac-SDKP from its precursor thymosin-ß₄. When we treated rats with a specific oral rolyl oligopeptidase inhibitor, Ac-SDKP decreased significantly in the plasma, heart, and kidney. In the present study, we tested the hypothesis that endogenous Ac-SDKP at basal levels plays a physiological role, antagonizing and/or preventing excessive collagen deposition. We studied whether chronic blockade of Ac-SDKP promotes collagen accumulation and/or accelerates this process in the presence of a profibrotic stimulus such as angiotensin II. We found that decreased basal levels of Ac-SDKP increased cardiac and renal perivascular fibrosis and promoted glomerulosclerosis. Moreover, in the presence of angiotensin II decreasing basal levels of Ac-SDKP accelerated interstitial cardiac fibrosis attributable to an increase in cells that produce collagen. We concluded that Ac-SDKP participates in the regulation of collagen content under normal conditions. We believe this is the first study showing that this peptide plays a physiological role at basal concentrations, preventing organ collagen accumulation.

Key Words: prolyl endopeptidase • thymosin ß₄ • angiotensin-converting enzyme • heart • kidney • collagen

This article has been cited by other articles:

				X. Liu, C. O. C. Bellamy, M. A. Bailey, L. J. Mullins, D. R. Dunbar, C. J. Kenyon, G. Brooker, S. Kantachuvesiri, K. Maratou, A. Ashek, et al. Angiotensin-converting Enzyme Is a Modifier of Hypertensive End Organ Damage J. Biol. Chem., June 5, 2009; 284(23): 15564 - 15572. [Abstract] [Full Text] [PDF]

				Y.-H. Liu, M. D'Ambrosio, T.-d. Liao, H. Peng, N.-E. Rhaleb, U. Sharma, S. Andre, H.-J. Gabius, and O. A. Carretero N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H404 - H412. [Abstract] [Full Text] [PDF]

				C.-X. Lin, N.-E. Rhaleb, X.-P. Yang, T.-D. Liao, M. A. D'Ambrosio, and O. A. Carretero Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1253 - H1261. [Abstract] [Full Text] [PDF]

				U. Sharma, N.-E. Rhaleb, S. Pokharel, P. Harding, S. Rasoul, H. Peng, and O. A. Carretero Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1226 - H1232. [Abstract] [Full Text] [PDF]